Journal article
Elevated levels of synaptic protein GAP‐43 associate with brain tauopathy, atrophy and cognition in Alzheimer’s disease
Kunal Dhiman, Victor LL Villemagne, Dhamidhu Eratne, Petra L Graham, Christopher J Fowler, Pierrick Bourgeat, Qiao‐Xin Li, Steven Collins, Ashley I Bush, Christopher C Rowe, David Ames, Colin L Masters, Kaj Blennow, Henrik Zetterberg, Ralph N Martins, Veer Bala Gupta
Alzheimer's & Dementia | Wiley | Published : 2020
DOI: 10.1002/alz.044098
Abstract
AbstractBackgroundSynaptic dysfunction is an early pathophysiological event, which associates with cognitive aberrations in Alzheimer’s disease (AD). Growth associated protein 43 (GAP‐43) is a nervous tissue specific protein, which plays a crucial role in axon formation, growth and synaptic plasticity. The current study evaluated the utility of cerebrospinal fluid (CSF) GAP‐43 in diagnosing AD, and its association with neuropathological and cognitive changes in AD, using CSF samples of participants from the Australian Imaging, Biomarkers and Lifestyle study of ageing (AIBL).MethodThe study participants (n=218) were clinically classified into healthy controls (HC, n=156), mild cognitive impai..
View full abstract